<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>17357574</identifier>
<setSpec>0300-9041</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Lira, Josefina</dc:author>
<dc:author>Vázquez, Juanita</dc:author>
<dc:author>Saldívar Rodríguez, Donato</dc:author>
<dc:author>Lara, Roger</dc:author>
<dc:author>Rodríguez, Ever</dc:author>
<dc:author>Ramos, Carlos</dc:author>
<dc:author>Romo, Jorge</dc:author>
<dc:description xml:lang="en">BACKGROUND The combined oral contraceptives are one of the most prescribed medicines. Across the years they have given to more than 60 million women of the whole world a suitable method for the highly reliable and effective natal control. The oral contraceptives are different from other medicines; principally they are not in use for controlling any disease and have the potential of giving advantages. OBJECTIVES To evaluate the control of the cycle, tolerability and acceptance of an oral contraceptive of ultralow dose with gestodene (60 microg) and ethinylestradiol (15 microg) in a population of healthy women from 18 to 35 years. PARTICIPANTS AND METHODS The study included adult healthy women, all the users signed assent of informed before being included to the study and of the beginning of any procedure in agreement with the declarations of Helsinki and its amendments. Descriptive statistics was used for the demographic information and the comparison between the initial and final visits of the variables of efficiency. There was used the test (Proof) of ranges of Wilcoxon's sign for related samples. RESULTS There were included 113 women. The average of age was 26.08 years (SD = 4.43), weight of 62.02 kg (SD = 11.13) and height of 159.20 cm (SD = 6.06). The distribution in four centers was: 32 in the University Hospital (Monterrey), 21 in the Country 2000 (Guadalajara), 30 in in the Medical Center La Mora (Aguascalientes) and 30 in Perinatology National Institute (Mexico City). CONCLUSIONS The contraceptive efficiency of the combination of 15 microg of ethinylestradiol and 60 microg of gestodene has been demonstrated in previous studies. This study ratifies the international results of efficiency and tolerability.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2006 Nov </dc:date>
<dc:title xml:lang="es">Experiencia clínica de los anticonceptivos orales combinados (AOC) de baja dosis en México.</dc:title>
<dc:title xml:lang="en">[Clinical experience of combined oral contraceptives of low doses in Mexico].</dc:title>
<dc:publisher>Ginecologia y obstetricia de Mexico</dc:publisher>
</metadata>
</record>
</pubmed-document>
